Table 1.
The general characteristic of the included studies
| Author | Country | Sample (I/C) | Age (I/C) | Surgery | Intervention | Control | Outcomes | Follow-up (weeks) | Study |
|---|---|---|---|---|---|---|---|---|---|
| Beckmann 2015 | USA | 54/54 | 35.1/35.1 | Hip arthroscopy | Naproxen (500 mg, twice daily, total 3 weeks | Placebo | 1,2,3,4,5 | 3 | RCTs |
| Vielpeau 1999 | France | 28/28 | 66/62.8 | THA | Naproxen (250 mg, 3 times daily, total 6 weeks) | Placebo | 1,2,3,5 | 6 | RCTs |
| Gebuhr 1991 | Denmark | 28/27 | 75/70 | THA | Naproxen (500 mg twice on operation day, 250 mg, 3 times daily, total 4 weeks) | Placebo | 2,3,5 | 4 | RCTs |
| Gebuhr 1995 | Denmark | 27/23 | 72/73 | THA | Naproxen (500 mg twice daily for 7 days from operation day on) | Placebo | 1,2,3,4 | 12 | RCTs |
1: the occurrence of HO at 1.5 months after surgery; 2: the occurrence of HO at 3 months after surgery; 3: the occurrence of HO at 6 months after surgery; 4: the occurrence of HO at 12 months after surgery; 5: the occurrence of complications
I intervention group, C control group, THA total hip arthroplasty